H. Robison

[783] SHORT-TERM ANTIVIRAL ACTIVITY AND SAFETY OF ACH-806 (GS-9132), AN NS4A ANTAGONIST, IN HCV GENOTYPE 1 INFECTED INDIVIDUALS

John C. Pottage, Eric Lawitz, Danièle Mazur et al. · Journal of Hepatology · 2007 · 25 citations

An Ns4a Antagonist, Medicine, Antiviral Drug Development +8

Rapid and Sharp Decline in HCV upon Monotherapy with Ns3 Protease Inhibitor, Ach-1625

Atul Agarwal, Bao Zhang, Elizabeth Olek et al. · Antiviral Therapy · 2012 · 15 citations

Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1-Infected Subjects

Philippe Colucci, John C. Pottage, H. Robison et al. · Antimicrobial Agents and Chemotherapy · 2008 · 13 citations · Full text

Pharmacological Study, Physiologically-based Pharmacokinetic Modeling, Human Retrovirus +15

LP06 : Sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: A phase 2 “proxy” study

Edward Gane, Christian Schwabe, Michael Mader et al. · Journal of Hepatology · 2015 · 13 citations

Clinical Trials, Antiviral Therapy, Translational Research +5

876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS

Andrew J. Muir, John M. Hill, E. Läwitz et al. · Journal of Hepatology · 2013 · 10 citations